Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications

Jay Grossman, Charles Banov, Peter Boggs, Edwin A. Bronsky, Robert J. Dockhorn, Howard Druce, Steven R. Findlay, John W. Georgitis, Frank C. Hampel, Harold Kaiser, Paul Ratner, David G. Tinkelman, Martin D. Valentine, Paul Roszko, Elena Zegarelli, Chester Wood

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.).

Original languageEnglish (US)
Pages (from-to)1123-1127
Number of pages5
JournalThe Journal of allergy and clinical immunology
Volume95
Issue number5 SUPPL.
DOIs
StatePublished - May 1995
Externally publishedYes

Keywords

  • Nonallergic rhinitis
  • chronic
  • efficacy
  • ipratropium
  • nasal spray
  • safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications'. Together they form a unique fingerprint.

Cite this